Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Breakthrough suggests new approach to brain disorders
The approach works by inducing nerve cells in the brain and the spine to release natural antioxidants that protect nerve cells from stress and free radicals that lead
The approach works by inducing nerve cells in the brain and the spine to release natural antioxidants that protect nerve cells from stress and free radicals that lead
VivaGel is currently being developed as a vaginal microbicide gel to prevent the transmission of genital herpes and HIV. VivaGel was also recently awarded $20 million by the
Innovive anticipates commencing phase I trials in the first half of 2006 to study the compound in the treatment of acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), non
Vivaglobin represents another treatment option for patients who may not easily tolerate the currently available intravenous method because they have poor venous access or experience serious side effects
Forteo, normally delivered via injection, was approved by the FDA for the treatment of osteoporosis in 2002. The development program will utilize the Alkermes Air pulmonary drug delivery
The combination of VX-950 and peg-IFN produced a median 5.5 log10 reduction in hepatitis C virus (HCV) RNA at day 14, which equates to a 300,000 fold reduction
In addition, Amgen has acquired non-exclusive worldwide rights for the development and commercialization of diagnostic products for human use based on the same gene. According to the terms
The company has retained the financial advisory firm Seven Hills Partners to help it to explore the various alternatives for the future of the company. “Our objective is
The phase I clinical trial is designed as an open-label, repeat dose-escalation study for the evaluation of the safety and tolerability of AVN944 in adult patients with advanced
Valortim is an investigational fully human antibody created using Medarex’s UltiMAb human antibody development system that targets the bacillus anthracis protective antigen. The FDA will now facilitate the